Curated News
By: NewsRamp Editorial Staff
March 10, 2026

LIXTE Acquires Liora's LiGHT Proton Therapy System for Cancer Treatment

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • LIXTE's acquisition of Liora Technologies provides a competitive edge by adding the cost-effective LiGHT proton therapy system to enhance its cancer treatment portfolio.
  • The LiGHT System uses a proton beam to deliver high dose rates to deep tumors, reducing installation costs and treatment sessions compared to current technologies.
  • This acquisition could improve cancer treatment accessibility by increasing patient capacity at treatment centers and potentially enhancing outcomes with advanced proton therapy.
  • LIXTE's new LiGHT System, developed from technology praised by a former CERN director, offers a novel approach to proton therapy for various cancers.

Impact - Why it Matters

This acquisition represents a significant convergence of pharmaceutical and technological approaches to cancer treatment that could transform patient care. The LiGHT System's ability to reduce both treatment costs and session frequency addresses two major barriers in cancer therapy: accessibility and patient burden. For cancer patients, this could mean more effective treatment of deep-seated tumors with fewer side effects and reduced time commitment. The combination of LIXTE's pharmaceutical expertise with Liora's technological innovation creates a comprehensive oncology platform that could accelerate the development of more effective, accessible cancer treatments. This development matters because cancer remains a leading cause of death worldwide, and innovations that improve treatment efficacy while reducing costs and treatment duration have the potential to save lives and improve quality of life for millions of patients globally.

Summary

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, has made a strategic acquisition that significantly expands its oncology treatment capabilities. The company recently acquired Liora Technologies, which is pioneering advanced proton therapy systems for treating various cancers. This acquisition brings Liora's proprietary flagship technology, the LiGHT System (Linac for Image Guided Hadron Therapy), under LIXTE's umbrella as a wholly owned subsidiary. According to Professor Steve Myers, former Director of Accelerators and Technology at CERN, the LiGHT System provides a proton beam that delivers very high dose rates to deep-seated tumors while offering unique biological effects that could revolutionize cancer treatment.

The LiGHT System represents a significant advancement in proton therapy technology, offering multiple advantages over current treatment options. Professor Myers emphasized that this innovative system will greatly reduce installation costs and decrease the number of treatment sessions needed compared to existing technologies. This efficiency improvement is expected to significantly increase the number of patients that treatment centers can serve, potentially making advanced cancer therapy more accessible to a broader patient population. The acquisition positions LIXTE at the forefront of both pharmaceutical and technological approaches to cancer treatment, creating a comprehensive oncology platform that addresses multiple aspects of cancer care.

LIXTE's existing pipeline includes its first-in-class lead clinical PP2A inhibitor, LB-100, which has demonstrated promising results in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies, potentially improving outcomes for patients with various cancers. The company's approach represents a pioneering effort in the new field of cancer biology known as activation lethality, advancing a novel treatment paradigm supported by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently underway for ovarian clear cell carcinoma and metastatic colon cancer, with additional information available through the InvestorBrandNetwork website.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, LIXTE Acquires Liora's LiGHT Proton Therapy System for Cancer Treatment

blockchain registration record for this content.